FISH Probe

Global FISH Probe Market to Reach US$1.4 Billion by 2030

The global market for FISH Probe estimated at US$971.7 Million in the year 2024, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Q-FISH, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$638.3 Million by the end of the analysis period. Growth in the Flow-FISH segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$253.3 Million While China is Forecast to Grow at 9.1% CAGR

The FISH Probe market in the U.S. is estimated at US$253.3 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$321.4 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global FISH Probe Market – Key Trends & Drivers Summarized

What Are FISH Probes and Why Are They Essential in Genetic Diagnostics?

Fluorescence In Situ Hybridization (FISH) Probes are specialized DNA or RNA sequences used in genetic testing to detect specific DNA sequences in chromosomes, identifying abnormalities associated with various diseases, such as cancer and genetic disorders. FISH probes work by binding, or “hybridizing,” to complementary DNA or RNA sequences in samples taken from patients, allowing for highly accurate visualization of genetic information. In the field of oncology, FISH probes are widely used to detect chromosomal abnormalities that may indicate the presence or progression of cancers like breast, lung, and bladder cancers. FISH technology is also essential in prenatal and postnatal diagnostics, where it is used to identify chromosomal anomalies associated with conditions such as Down syndrome and other genetic disorders.

The precision and rapid turnaround of FISH probes make them a critical tool in personalized medicine, where genetic information guides treatment decisions tailored to an individual`s specific genetic makeup. This capability is particularly valuable in oncology, where FISH results can inform targeted therapies that enhance treatment efficacy and improve patient outcomes. As the demand for precise genetic diagnostics continues to rise, FISH probes are becoming increasingly central in both clinical and research settings, providing insights that support early diagnosis and more effective disease management.

How Are Technological Advancements Shaping the FISH Probe Market?

Technological advancements are driving the FISH probe market by enhancing probe sensitivity, accuracy, and usability. Recent developments include the use of multicolor FISH probes, which allow for simultaneous detection of multiple genetic abnormalities in a single sample, making the diagnostic process faster and more comprehensive. Multicolor FISH is especially valuable in oncology, where the ability to assess multiple chromosomal alterations in tumor cells can provide a detailed genetic profile that supports precision treatment planning. Additionally, automation in FISH testing has increased efficiency and reproducibility, allowing laboratories to process higher volumes of samples with improved accuracy, meeting the rising demand for genetic testing in clinical settings.

Furthermore, advancements in molecular biology have led to the development of more specific and robust probes that reduce the likelihood of false positives or negatives, increasing diagnostic reliability. AI and machine learning are also beginning to play a role in FISH probe analysis, automating data interpretation to assist healthcare providers in making faster and more accurate diagnoses. These technological enhancements are transforming the FISH probe market, making genetic testing more accessible, precise, and efficient, and solidifying its role as a staple in modern diagnostics.

What Role Does Personalized Medicine Play in the Demand for FISH Probes?

The trend toward personalized medicine is a major driver of demand for FISH probes, as healthcare providers increasingly rely on genetic information to tailor treatments to individual patient profiles. FISH probes allow for detailed chromosomal mapping, which helps identify specific genetic alterations that may influence how a patient responds to a particular treatment. In cancer care, for example, FISH probes are used to identify genetic markers that indicate whether a patient may benefit from targeted therapies, such as HER2 inhibitors for breast cancer or EGFR inhibitors for lung cancer. By providing accurate and actionable genetic insights, FISH technology enables more precise treatment strategies that improve patient outcomes and reduce the likelihood of adverse effects.

In addition to oncology, personalized medicine in fields such as reproductive health, neurology, and rare genetic disorders also relies on FISH probes for diagnostic and prognostic insights. As personalized medicine continues to gain momentum, the need for precise genetic diagnostic tools like FISH probes is expected to increase. This trend is particularly strong in regions with advanced healthcare infrastructure, such as North America and Europe, where genetic testing is integral to modern healthcare.

What Factors Are Driving Growth in the FISH Probe Market?

The growth in the FISH Probe market is driven by increasing demand for genetic testing, technological advancements in probe design and automation, the rising prevalence of genetic disorders and cancers, and the emphasis on personalized medicine. As awareness and diagnosis of genetic conditions grow, there is a corresponding demand for FISH probes, which provide fast, accurate results for a wide range of genetic abnormalities. Technological innovations, such as multicolor probes and automation, are enhancing the throughput and precision of FISH testing, making it an accessible and efficient tool in genetic diagnostics.

The rise of personalized medicine, especially in oncology, is also a major growth driver, as healthcare providers use FISH probes to guide targeted therapies that improve treatment efficacy. Additionally, the increasing incidence of cancer and genetic disorders globally is prompting healthcare systems to adopt FISH technology to ensure timely and accurate diagnoses. Together, these factors—rising genetic testing demand, technological advancement, growth of personalized medicine, and the prevalence of genetic diseases—are fueling expansion in the FISH Probe market, establishing it as an essential component of modern healthcare diagnostics and treatment planning.

SCOPE OF STUDY:

The report analyzes the FISH Probe market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Technology (Q-FISH, Flow-FISH, Other Technologies); End-Use (Clinical, Research, Companion Diagnostics)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 33 Featured) -

• Abnova Corporation
• Agilent Technologies
• Biocare Medical, LLC
• Biodot Inc.
• Biosearch Technologies Inc.
• Exiqon A/S
• F. Hoffmann-La Roche Ltd.
• Genemed Biotechnologies, Inc.
• Gsp Research Institute, Inc.
• Horizon Diagnostics
• Merck KGAA
• Oxford Gene Technology
• Perkinelmer Inc
• Thermo Fisher Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs CBob geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.